Catalog No.
DHC90703
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Mouse
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P11836
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
In-111 Zevalin, Y-90 Zevalin, CAS: 206181-63-7
Clone ID
Ibritumomab
Ibritumomab tiuxetan (Zevalin) and elevated serum human anti-murine antibody (HAMA), PMID: 29406240
Zevalin(®) (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?, PMID: 27497027
Ibritumomab tiuxetan for non-Hodgkin's lymphoma, PMID: 16761929
Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma, PMID: 15045033
Yttrium 90 Ibritumomab Tiuxetan, PMID: 29999770
Indium 111 Ibritumomab Tiuxetan, PMID: 29999760
90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr, PMID: 26657116
Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice, PMID: 15154741
Yttrium 90 ibritumomab tiuxetan in lymphoma, PMID: 16840185
The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma, PMID: 16207072
Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin's lymphoma, PMID: 15498147
Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin), PMID: 14710399
90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma, PMID: 15268665
Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin), PMID: 14762739
90Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma, PMID: 12777454
Rituximab-PECC induction followed by 90 Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study, PMID: 31290569
Long-term outcomes of frontline 90 Y-ibritumomab tiuxetan in marginal zone lymphoma, PMID: 32755329
Radiation safety with yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy, PMID: 15160857
[Radioimmunotherapy with 90Y-ibritumomab tiuxetan in lymphomas], PMID: 16540015
Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study, PMID: 32203140
Consolidation with 90 Yttrium-ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma, PMID: 32978820
Ibritumomab tiuxetan, PMID: 12629947
Logistics of therapy with the ibritumomab tiuxetan regimen, PMID: 16979437
90 Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study, PMID: 31944265
Nursing a patient during and after 90Y-ibritumomab tiuxetan (Zevalin) therapy, PMID: 15154742
Dosimetry in patients with B-cell lymphoma treated with [(90)Y]ibritumomab tiuxetan or [(131)I]tositumomab, PMID: 21386787
Radiation safety guidelines for radioimmunotherapy with yttrium 90 ibritumomab tiuxetan, PMID: 14983760
90 Y-ibritumomab-tiuxetan as a therapeutic alternative for follicular lymphoma (FL): A single-center experience, PMID: 29993147
Efficacy and safety of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin), PMID: 15160856
Radiation safety considerations with yttrium 90 ibritumomab tiuxetan (Zevalin), PMID: 14762741
Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma, PMID: 14710398
Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetan, PMID: 18220907
Outcomes after (90) Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis, PMID: 24740968
Yttrium 90 ibritumomab tiuxetan (Zevalin): a new bullet in the fight against malignant lymphoma?, PMID: 17886241
Educating patients about radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin), PMID: 15160858
Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma, PMID: 15802280
Safety of 90 Y-ibritumomab Tiuxetan Treatment for Japanese Patients in Real-world Clinical Practice, PMID: 30606920
Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin), PMID: 14762738
Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice, PMID: 17942813
Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin), PMID: 14710397
Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab, PMID: 17530015
The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry, PMID: 16269594
Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma, PMID: 15786024
Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET, PMID: 22218876
Heterogeneity of intratumoral (111)In-ibritumomab tiuxetan and (18)F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin's lymphoma, PMID: 25853016
Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology, PMID: 20095035
Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001, PMID: 32658627
Yttrium-90 ibritumomab tiuxetan consolidation versus rituximab maintenance therapy after induction chemotherapy in patients with indolent non-Hodgkin lymphoma: a single-institution experience, PMID: 31496425
Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature, PMID: 15636698
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma, PMID: 11842394
For research use only. Not for human or drug use.
